EZH2、p53、Ki-67在结直肠腺癌及腺瘤组织中的表达及相关性探讨
|
摘要
目的探讨EZH2、p53及Ki-67在结直肠腺癌及腺癌组织中表达的相关性。方法采用免疫组织化学法分析检测82例结直肠腺癌标本、49例结直肠腺瘤标本及40例正常结直肠粘膜组织标本中EZH2蛋白、p53及Ki-67的表达情况。结果 EZH2在结直肠腺癌、结直肠腺瘤、正常结直肠粘膜组织中表达的阳性率分别为80.49%、40.82%、5%;p53在结直肠腺癌、结直肠腺瘤和正常结直肠粘膜组织中表达的阳性率分别为42.68%、6.12%和1.02%;Ki-67在结直肠腺癌、结直肠腺瘤和正常结直肠粘膜组织中表达的阳性率分别为57.31%、26.53%和2.5%,差异均有统计学意义(P <0.05)。EZH2、p53、ki-67蛋白的阳性表达与患者的年龄、性别无关(P> 0.05),与肿瘤细胞的分化程度、浸润深度、有无淋巴结转移、TNM分期有关(P <0.05),且EZH2、p53与Ki-67的在结直肠腺癌组织中表达呈正相关(P <0.05)。结论 EZH2、p53、Ki-67在结直肠腺癌组织中均有不同程度的高表达,且与结直肠腺癌的浸润及转移密切相关,且EZH2、p53与Ki-67在结直肠腺癌组织中的表达呈正相关,联合检测对评估结直肠腺癌病情轻重、进展、治疗及预后有重要意义。
Objective To invesgate the expression of EZH2、p53 and Ki-67 in colorectal adenocarcino-ma,adenoma and nomal tissue,evaluate the collection of the expression of EZH2、p53 and Ki-67 in colorectaladenocarcinoma and its′ clinical significance.MethodsBy using immunohistochemical method,testing theexpression of EZH2,p53 and Ki-67 in 82 cases of colorectal adenocarcinoma、49 cases of adenoma and 40 cases ofnomal tissue.ResultsThe positive expression of EZH2 in colorectal adenocarcinoma、adenoma and nomal tissueare 80.49%,40.82%,5% respectively. The positive expression of p53 in colorectal adenocarcinoma、adenoma andnomal tissue are 42.68%,6.12%,0% respectively. The positive expression of Ki-67 in colorectal adenocarcinoma、adenoma and nomal tissue are 57.31%,26.53%,2.5% respectively. The difference was statistically significant(P < 0.05). The expressions of EZH2,p53 and Ki-67 have nothing to do with the patients gender and age(P <0.05),but were closely related to the differentiated degree,neoplasm′s position,lymphatic metastasis and TNMstages(P < 0.05). In colorectal adenocarcinoma the expression of EZH2,p53 and Ki-67 were positive correlation(P < 0.05).ConclusionEZH2,p53 and Ki-67 were highly expressed in colorectal adenocarcinoma tissues,and were closely related to the invasion and metastasis of colorectal adenocarcinoma. The expression of EZH2,p53 and Ki-67 were positive correlation. So the combined detection of EZH2,p53 and Ki-67 is of great significance inevaluating the severity,progression,treatment and prognosis of colorectal adenocarcinoma.
Objective To invesgate the expression of EZH2、p53 and Ki-67 in colorectal adenocarcino-ma,adenoma and nomal tissue,evaluate the collection of the expression of EZH2、p53 and Ki-67 in colorectaladenocarcinoma and its′ clinical significance.MethodsBy using immunohistochemical method,testing theexpression of EZH2,p53 and Ki-67 in 82 cases of colorectal adenocarcinoma、49 cases of adenoma and 40 cases ofnomal tissue.ResultsThe positive expression of EZH2 in colorectal adenocarcinoma、adenoma and nomal tissueare 80.49%,40.82%,5% respectively. The positive expression of p53 in colorectal adenocarcinoma、adenoma andnomal tissue are 42.68%,6.12%,0% respectively. The positive expression of Ki-67 in colorectal adenocarcinoma、adenoma and nomal tissue are 57.31%,26.53%,2.5% respectively. The difference was statistically significant(P < 0.05). The expressions of EZH2,p53 and Ki-67 have nothing to do with the patients gender and age(P <0.05),but were closely related to the differentiated degree,neoplasm′s position,lymphatic metastasis and TNMstages(P < 0.05). In colorectal adenocarcinoma the expression of EZH2,p53 and Ki-67 were positive correlation(P < 0.05).ConclusionEZH2,p53 and Ki-67 were highly expressed in colorectal adenocarcinoma tissues,and were closely related to the invasion and metastasis of colorectal adenocarcinoma. The expression of EZH2,p53 and Ki-67 were positive correlation. So the combined detection of EZH2,p53 and Ki-67 is of great significance inevaluating the severity,progression,treatment and prognosis of colorectal adenocarcinoma.
引文
[1]刘晓雪,宇传华,周薇,等.中国近30年间结直肠腺癌死亡趋势分析[J].中国癌症杂志,2018,28(3):177-183.
[2]LI H,CHANG C,SHANG Y,et al.A missense variant in EZH2 is associated with colorectal cancer risk in a Chinese population[J].Oncotarget,2017,8(55):94738-94742.
[3]ALZRIGAT M,PARRAGA A A,AGARWAL P,et al.EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential rumor suppressor functions[J].Oncotarget,2017,8(6):10213-10224.
[4]BUGIDE S,GREEN M R,WAJAPEYEE N.Inhibition of EZH2induces natural killer cell-mediated eradication of hepatocellular carcinoma cells[J].P Natl Acad Sci USA,2018,115(15):E3509.
[5]WEN Y,CAI J,HOU Y,et al.Role of EZH2 in cancer stem cells:from insight to a therapeutic target[J].Oncotarget,2017,8(23):37974-37990.
[6]梁珊凤,李春艳,黎昭兰,等.沉默EZH2表达抑制胆管癌QBC939细胞增殖及其机制[J].实用医学杂志,2017,33(10):1584-1588.
[7]DAURES M,IDRISSOU M,JUDES G,et al.A new metabolic gene signature in prostate cancer regulated by JMJD3 and EZH2[J].Oncotarget,2018,9(34):23413-23425.
[8]CHIEN Y C,LIU L C,YE H Y,et al.EZH2 promotes migration and invasion of triple-negative breast cancer cells via regulating TIMP2-MMP-2/-9 pathway[J].Am J Cancer Res,2018,8(3):422-434.
[9]CHEN Z,YANG P,LI W.Expression of EZH2 is associated with poor outcome in colorectal cancer[J].Oncology Letters,2018,15(3):2953-2961.
[10]张立成,周毅.结直肠腺癌组织中EZH2、Caspase-3蛋白的表达变化及意义[J].山东医药,2017,57(25):48-50.
[11]FLORES E R.Commentary on“apoptosis,p53,and tumor cell sensitivity to anticancer agents”[J].Cancer Res,2016,76(23):6763.
[12]ITAHANA Y,ITAHANA K.Emerging roles of p53 family memembers in glucose metabolism[J].Int J Mol Sci,2018,19(3):776.
[13]BLANDINO G,DI S A.New therapeutic strategies to treat human cancers expressing mutant p53 proteins[J].J Exp Clin Canc Res,2018,37(1):30.
[14]卞雪春,余艳兰,赵平,等.结直肠腺癌组织RSK4、p53蛋白的表达及临床病理意义[J].现代生物医学进展,2018,18(6):1102-1106.
[15]YANG Y,LI J,JIN L.Independent correlation between ki-67index and circulating tumor cells in the diagnosis of colorectal cancer[J].Anticancer Res,2017,37(8):4693-4700.
[16]TANG M YOU G,LIN L,et al.Expression and clinical significance of EZH2 and Ki67 in cervical carcinoma[J].CN J Clin Obstet Gynecol,2018,(1):12-15.
[17]孙旭凌,申婧,黄桂林,等.结直肠腺癌HER2及Ki-67表达的关系及预后因素分析[J].重庆医学,2018,48(12):1610-1615.
[18]SMONSKEY M,LASORSA E,ROSARIO S,et al.EZH2 inhibition re-sensitizes multidrug resistant B-cell lymphomas to etoposide mediated apoptosis[J].Oncoscience,2016,3(1):21-30.
[19]YOO K H,HENNIGHAUSEN L.EZH2 methyltransferase and H3K27 methylation in breast cancer[J].Int J Biol Sci,2012,8(1):59-65.
[2]LI H,CHANG C,SHANG Y,et al.A missense variant in EZH2 is associated with colorectal cancer risk in a Chinese population[J].Oncotarget,2017,8(55):94738-94742.
[3]ALZRIGAT M,PARRAGA A A,AGARWAL P,et al.EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential rumor suppressor functions[J].Oncotarget,2017,8(6):10213-10224.
[4]BUGIDE S,GREEN M R,WAJAPEYEE N.Inhibition of EZH2induces natural killer cell-mediated eradication of hepatocellular carcinoma cells[J].P Natl Acad Sci USA,2018,115(15):E3509.
[5]WEN Y,CAI J,HOU Y,et al.Role of EZH2 in cancer stem cells:from insight to a therapeutic target[J].Oncotarget,2017,8(23):37974-37990.
[6]梁珊凤,李春艳,黎昭兰,等.沉默EZH2表达抑制胆管癌QBC939细胞增殖及其机制[J].实用医学杂志,2017,33(10):1584-1588.
[7]DAURES M,IDRISSOU M,JUDES G,et al.A new metabolic gene signature in prostate cancer regulated by JMJD3 and EZH2[J].Oncotarget,2018,9(34):23413-23425.
[8]CHIEN Y C,LIU L C,YE H Y,et al.EZH2 promotes migration and invasion of triple-negative breast cancer cells via regulating TIMP2-MMP-2/-9 pathway[J].Am J Cancer Res,2018,8(3):422-434.
[9]CHEN Z,YANG P,LI W.Expression of EZH2 is associated with poor outcome in colorectal cancer[J].Oncology Letters,2018,15(3):2953-2961.
[10]张立成,周毅.结直肠腺癌组织中EZH2、Caspase-3蛋白的表达变化及意义[J].山东医药,2017,57(25):48-50.
[11]FLORES E R.Commentary on“apoptosis,p53,and tumor cell sensitivity to anticancer agents”[J].Cancer Res,2016,76(23):6763.
[12]ITAHANA Y,ITAHANA K.Emerging roles of p53 family memembers in glucose metabolism[J].Int J Mol Sci,2018,19(3):776.
[13]BLANDINO G,DI S A.New therapeutic strategies to treat human cancers expressing mutant p53 proteins[J].J Exp Clin Canc Res,2018,37(1):30.
[14]卞雪春,余艳兰,赵平,等.结直肠腺癌组织RSK4、p53蛋白的表达及临床病理意义[J].现代生物医学进展,2018,18(6):1102-1106.
[15]YANG Y,LI J,JIN L.Independent correlation between ki-67index and circulating tumor cells in the diagnosis of colorectal cancer[J].Anticancer Res,2017,37(8):4693-4700.
[16]TANG M YOU G,LIN L,et al.Expression and clinical significance of EZH2 and Ki67 in cervical carcinoma[J].CN J Clin Obstet Gynecol,2018,(1):12-15.
[17]孙旭凌,申婧,黄桂林,等.结直肠腺癌HER2及Ki-67表达的关系及预后因素分析[J].重庆医学,2018,48(12):1610-1615.
[18]SMONSKEY M,LASORSA E,ROSARIO S,et al.EZH2 inhibition re-sensitizes multidrug resistant B-cell lymphomas to etoposide mediated apoptosis[J].Oncoscience,2016,3(1):21-30.
[19]YOO K H,HENNIGHAUSEN L.EZH2 methyltransferase and H3K27 methylation in breast cancer[J].Int J Biol Sci,2012,8(1):59-65.